Safety and efficacy of new anticoagulants in patients with heart failure

Related Experiment Video

Updated: May 16, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Ron Pisters1, Gregory Y H Lip

  • 1University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK.

Current Heart Failure Reports
|December 12, 2012
PubMed

Insights

Oral anticoagulation may prevent thromboembolism in heart failure (HF) patients, particularly stroke, but carries bleeding risks. New oral anticoagulants and better risk assessment may improve future prevention strategies for HF patients.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Pharmacology

Background:

  • Heart failure (HF) is a prevalent condition associated with high morbidity and mortality.
  • Thromboembolism significantly worsens the prognosis for patients with heart failure.
  • Atrial fibrillation (AF) frequently co-occurs with HF, further elevating thromboembolic risk.

Purpose of the Study:

  • To review the evidence on anticoagulation efficacy in heart failure patients.
  • To assess the balance between thromboembolic risk reduction and bleeding risk.
  • To explore future strategies for thromboembolic prevention in HF.

Main Methods:

  • Systematic review of existing evidence on anticoagulation in HF.
  • Analysis of thromboembolic event rates and bleeding complications.
  • Consideration of factors influencing treatment decisions, including HF cohort heterogeneity and AF diagnosis.

Main Results:

  • Oral anticoagulation shows potential for preventing thromboembolism, including stroke, in HF patients.
  • Anticoagulation therapy is associated with an increased risk of major bleeding.
  • The effectiveness is influenced by patient selection, AF diagnosis, and bleeding risk assessment.

Conclusions:

  • Despite bleeding risks, anticoagulation offers potential benefits for thromboembolic prevention in HF.
  • Advances in understanding bleeding risk and new oral anticoagulants may enhance future therapeutic strategies.
  • Improved outcomes for HF patients are anticipated with optimized thromboembolic prevention.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.